Takeda is said to be considering a bid for rare disease specialist Shire that could top $40 billion. Shire's shares were up as much as 26 % on the news.
It is considered that Takeda’s public statement that it is considering an approach for Shire will inevitably flush out other big pharma players including Pfizer, Novartis and AbbVie, leading to a competitive M&A situation.
As posted in January, Takeda has been active over the past year or so in seeking rare disease deals/collaborations to bolster its neuroscience division.
https://www.cnbc.com/2018/03/28/japans-takeda-is-considering-a-bid-for-british-drugmaker-shire.html
https://hotcopper.com.au/threads/2017-2018.3940742/page-82?post_id=30121049#.WrwYQIhuaUk
Add to My Watchlist
What is My Watchlist?
